PURPOSE: Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days. METHODS: The primary objective of this study was to assess the response rate (confirmed complete and partial responses) of gemcitabine and capecitabine used in advanced/metastatic biliary neoplasms. Secondary objectives included overall survival and toxicities. RESULTS: The study accrued 57 patients from September 2003 to April 2005. Three patients were ineligible, and two others received no treatment. Characteristics of analyzable patients: 35 (67%) cholangiocarcinoma, 17 (33%) gallbladder cancer; PS 0 (18 pts), 1 (26 pts), 2 (8 pts); 26 (50%) men; median age 58.8 years (29.5-85.6). Among 51 patients evaluated for toxicity, 6 experienced grade 4 toxicities. Among 52 patients, there were 7 confirmed partial responses for a confirmed response probability of 13% (95% CI: 6-26%). Six patients had an unconfirmed partial response for an overall response probability of 25% (95% CI: 14-39%). Twelve patients (23%) demonstrated stable disease. The 6-month overall survival was 55% (95% CI: 41-69%), and median survival was 7 months (95% CI: 5-8 months). CONCLUSIONS: The combination of gemcitabine and capecitabine is a well-tolerated regimen with activity in patients with advanced gallbladder cancer and cholangiocarcinoma.
PURPOSE:Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days. METHODS: The primary objective of this study was to assess the response rate (confirmed complete and partial responses) of gemcitabine and capecitabine used in advanced/metastatic biliary neoplasms. Secondary objectives included overall survival and toxicities. RESULTS: The study accrued 57 patients from September 2003 to April 2005. Three patients were ineligible, and two others received no treatment. Characteristics of analyzable patients: 35 (67%) cholangiocarcinoma, 17 (33%) gallbladder cancer; PS 0 (18 pts), 1 (26 pts), 2 (8 pts); 26 (50%) men; median age 58.8 years (29.5-85.6). Among 51 patients evaluated for toxicity, 6 experienced grade 4 toxicities. Among 52 patients, there were 7 confirmed partial responses for a confirmed response probability of 13% (95% CI: 6-26%). Six patients had an unconfirmed partial response for an overall response probability of 25% (95% CI: 14-39%). Twelve patients (23%) demonstrated stable disease. The 6-month overall survival was 55% (95% CI: 41-69%), and median survival was 7 months (95% CI: 5-8 months). CONCLUSIONS: The combination of gemcitabine and capecitabine is a well-tolerated regimen with activity in patients with advanced gallbladder cancer and cholangiocarcinoma.
Authors: Cathy Eng; Ramesh K Ramanathan; Ramesh K Ramathan; Michael K Wong; Scot C Remick; Lanting Dai; Kurombi T Wade-Oliver; Sridhar Mani; Hedy L Kindler Journal: Am J Clin Oncol Date: 2004-12 Impact factor: 2.339
Authors: Michael V Mandola; Jan Stoehlmacher; Wu Zhang; Susan Groshen; Mimi C Yu; Syma Iqbal; Heinz-Josef Lenz; Robert D Ladner Journal: Pharmacogenetics Date: 2004-05
Authors: Margaret Tempero; William Plunkett; Veronique Ruiz Van Haperen; John Hainsworth; Howard Hochster; Renato Lenzi; James Abbruzzese Journal: J Clin Oncol Date: 2003-07-28 Impact factor: 44.544
Authors: Renuka V Iyer; John Gibbs; Boris Kuvshinoff; Marwan Fakih; James Kepner; Nancy Soehnlein; David Lawrence; Milind M Javle Journal: Ann Surg Oncol Date: 2007-08-19 Impact factor: 5.344
Authors: Ting Deng; Hong Pan; Rubing Han; Dingzhi Huang; Hongli Li; Likun Zhou; Xia Wang; Ming Bai; Xiang Li; Rui Liu; Shaohua Ge; Tao Ning; Le Zhang; Yi Ba Journal: Int J Clin Exp Med Date: 2014-12-15
Authors: Susanna V Ulahannan; Osama E Rahma; Austin G Duffy; Oxana V Makarova-Rusher; Metin Kurtoglu; David J Liewehr; Seth M Steinberg; Tim F Greten Journal: Hepat Oncol Date: 2015-01-01
Authors: Maria Castelo Branco; Fernanda Estevinho; João Correia Pinto; Mrinalini Honavar; Carlos Raposo; Ana Catarina Silva; Carlos Sottomayor Journal: J Gastrointest Cancer Date: 2019-09
Authors: Jennifer Yang; Matthew R Farren; Daniel Ahn; Tanios Bekaii-Saab; Gregory B Lesinski Journal: Expert Opin Ther Targets Date: 2017-03-17 Impact factor: 6.902
Authors: Chao Yang; Ming Xu; Huo-Jian Shen; Hong-Yi Zhu; Fu Li; Min He; Tao Chen; Jian Wang; Wei-Jin Shi; Fu Ji Journal: Int J Clin Exp Pathol Date: 2014-01-15
Authors: Edgar Ben-Josef; Katherine A Guthrie; Anthony B El-Khoueiry; Christopher L Corless; Mark M Zalupski; Andrew M Lowy; Charles R Thomas; Steven R Alberts; Laura A Dawson; Kenneth C Micetich; Melanie B Thomas; Abby B Siegel; Charles D Blanke Journal: J Clin Oncol Date: 2015-05-11 Impact factor: 50.717